Testicular cancer · 7 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
GIP Variant #01 | — | R 14 703 | 21d | — | — | — | — | — |
VeIP Variant #01 | — | R 12 305 | 21d | — | — | — | — | — |
VIP Variant #01 | — | R 10 535 | 21d | — | — | — | — | — |
TIP Variant #01 | — | R 8 405 | 28d | — | — | — | — | — |
Cisplatin and Epirubicin Variant #01 | — | R 2 458 | 21d | — | — | — | — | 1 |
Carboplatin and Etoposide (CE) Variant #10 | — | R 2 265 | 21d | ~4.6 mo | ~10.6 mo | ~7 | ~R 15 853 PFS proxy · indirect | 17 |
Ifosfamide and Paclitaxel N/A - secondary systemic drug | — | R 1 375 | 21d | — | ~21.3 mo | — | — | 2 |
7 of 7 regimens shown